253 related articles for article (PubMed ID: 38067120)
1. PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response.
Ansardamavandi A; Nikfarjam M; He H
Cells; 2023 Nov; 12(23):. PubMed ID: 38067120
[TBL] [Abstract][Full Text] [Related]
2. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
Wang K; Baldwin GS; Nikfarjam M; He H
World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
[TBL] [Abstract][Full Text] [Related]
4. PAKs in Human Cancer Progression: From Inception to Cancer Therapeutic to Future Oncobiology.
Kumar R; Li DQ
Adv Cancer Res; 2016; 130():137-209. PubMed ID: 27037753
[TBL] [Abstract][Full Text] [Related]
5. The role of p21-activated kinases in pancreatic cancer.
Yeo D; He H; Baldwin GS; Nikfarjam M
Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
[TBL] [Abstract][Full Text] [Related]
6. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
[TBL] [Abstract][Full Text] [Related]
7. The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma.
Ma Y; Nikfarjam M; He H
Cancer Lett; 2022 Nov; 548():215868. PubMed ID: 36027997
[TBL] [Abstract][Full Text] [Related]
8. Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation.
Liang Q; Zhou L; Li Y; Liu J; Liu Y
J Drug Target; 2022 Feb; 30(2):119-130. PubMed ID: 33960252
[TBL] [Abstract][Full Text] [Related]
9. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
10. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.
Menges CW; Sementino E; Talarchek J; Xu J; Chernoff J; Peterson JR; Testa JR
Mol Cancer Res; 2012 Sep; 10(9):1178-88. PubMed ID: 22798428
[TBL] [Abstract][Full Text] [Related]
11. Improved Immunotherapy Efficacy by Vascular Modulation.
Newport EL; Pedrosa AR; Njegic A; Hodivala-Dilke KM; Muñoz-Félix JM
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680355
[TBL] [Abstract][Full Text] [Related]
12. Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.
Belli S; Pesapane A; Servetto A; Esposito D; Napolitano F; Ascione CM; Allotta A; Zambrano N; Marino FZ; Franco R; Troiani T; Formisano L; Bianco R
Br J Cancer; 2023 Oct; 129(7):1071-1082. PubMed ID: 37568037
[TBL] [Abstract][Full Text] [Related]
13. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
Luheshi NM; Coates-Ulrichsen J; Harper J; Mullins S; Sulikowski MG; Martin P; Brown L; Lewis A; Davies G; Morrow M; Wilkinson RW
Oncotarget; 2016 Apr; 7(14):18508-20. PubMed ID: 26918344
[TBL] [Abstract][Full Text] [Related]
14. The p21-activated kinase, PAK2, is important in the activation of numerous pancreatic acinar cell signaling cascades and in the onset of early pancreatitis events.
Nuche-Berenguer B; Ramos-Álvarez I; Jensen RT
Biochim Biophys Acta; 2016 Jun; 1862(6):1122-36. PubMed ID: 26912410
[TBL] [Abstract][Full Text] [Related]
15. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
16. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
17. p21-activated kinases and gastrointestinal cancer.
He H; Baldwin GS
Biochim Biophys Acta; 2013 Jan; 1833(1):33-9. PubMed ID: 23092728
[TBL] [Abstract][Full Text] [Related]
18. The mechanistic immunosuppressive role of the tumour vasculature and potential nanoparticle-mediated therapeutic strategies.
Ileiwat ZE; Tabish TA; Zinovkin DA; Yuzugulen J; Arghiani N; Pranjol MZI
Front Immunol; 2022; 13():976677. PubMed ID: 36045675
[TBL] [Abstract][Full Text] [Related]
19. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
Yeo D; Huynh N; Beutler JA; Christophi C; Shulkes A; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2014 May; 346(2):264-72. PubMed ID: 24491405
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
Wang K; Baldwin GS; Nikfarjam M; He H
Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
